nafronyl has been researched along with Seizures in 2 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Status epilepticus (SE) triggered by lithium-pilocarpine is a model of epileptogenesis widely used in rats, reproducing many of the pathological features of human temporal lobe epilepsy (TLE)." | 8.31 | The vasodilator naftidrofuryl attenuates short-term brain glucose hypometabolism in the lithium-pilocarpine rat model of status epilepticus without providing neuroprotection. ( Delgado, M; Fernández de la Rosa, R; García-García, L; Gomez, F; Pozo, MÁ, 2023) |
| "Status epilepticus (SE) triggered by lithium-pilocarpine is a model of epileptogenesis widely used in rats, reproducing many of the pathological features of human temporal lobe epilepsy (TLE)." | 4.31 | The vasodilator naftidrofuryl attenuates short-term brain glucose hypometabolism in the lithium-pilocarpine rat model of status epilepticus without providing neuroprotection. ( Delgado, M; Fernández de la Rosa, R; García-García, L; Gomez, F; Pozo, MÁ, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-García, L | 2 |
| Gomez, F | 2 |
| Delgado, M | 2 |
| Fernández de la Rosa, R | 2 |
| Pozo, MÁ | 2 |
| Pohlmann-Eden, B | 1 |
| Linden, D | 1 |
| Bergler, W | 1 |
2 other studies available for nafronyl and Seizures
| Article | Year |
|---|---|
The vasodilator naftidrofuryl attenuates short-term brain glucose hypometabolism in the lithium-pilocarpine rat model of status epilepticus without providing neuroprotection.
Topics: Animals; Brain; Disease Models, Animal; Glucose; Hippocampus; Humans; Lithium; Nafronyl; Neuroprotec | 2023 |
The vasodilator naftidrofuryl attenuates short-term brain glucose hypometabolism in the lithium-pilocarpine rat model of status epilepticus without providing neuroprotection.
Topics: Animals; Brain; Disease Models, Animal; Glucose; Hippocampus; Humans; Lithium; Nafronyl; Neuroprotec | 2023 |
The vasodilator naftidrofuryl attenuates short-term brain glucose hypometabolism in the lithium-pilocarpine rat model of status epilepticus without providing neuroprotection.
Topics: Animals; Brain; Disease Models, Animal; Glucose; Hippocampus; Humans; Lithium; Nafronyl; Neuroprotec | 2023 |
The vasodilator naftidrofuryl attenuates short-term brain glucose hypometabolism in the lithium-pilocarpine rat model of status epilepticus without providing neuroprotection.
Topics: Animals; Brain; Disease Models, Animal; Glucose; Hippocampus; Humans; Lithium; Nafronyl; Neuroprotec | 2023 |
[Convulsive crises and cardiovascular complications following high-dosage parenteral administration of naftidrofuryl].
Topics: Adult; Cardiovascular Diseases; Humans; Infusions, Intravenous; Male; Nafronyl; Seizures; Time Facto | 1991 |